Regeneron Pharmaceuticals, Inc.
REGNLast close · Oct 16, 2026790.74−5.60 (−0.70%)
Market cap$81.4B
Key indicators
Revenue15.5B+9.3% on a year earlier
6.7B
7.9B
8.5B
16.1B
12.2B
13.1B
14.2B
14.3B
15.5B
17.5B
18.8B
20.1B
Fiscal year
FY201818
FY201919
FY202020
FY202121
FY202222
FY202323
FY202424
FY202525
TTMTTM
FY2026E26E
FY2027E27E
FY2028E28E
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||||||
| 6.7B | 7.9B+17.2% | 8.5B+8.1% | 16.1B+89.1% | 12.2B−24.3% | 13.1B+7.8% | 14.2B+8.3% | 14.3B+1.0% | 15.5B+9.3% | 17.5B | 18.8B | 20.1B | |
| — | 17.2% | 8.1% | 89.1% | -24.3% | 7.8% | 8.3% | 1.0% | 9.3% | 22.3% | 7.0% | 7.1% | |
| $21.29 | $18.46−13.3% | $30.52+65.3% | $71.97+135.8% | $38.22−46.9% | $34.77−9.0% | $38.34+10.3% | $41.48+8.2% | $40.38+1.7% | $58.36 | $62.54 | $69.64 | |
| Profitability | ||||||||||||
| 37.8% | 28.1%−9.7 pt | 42.1%+14.0 pt | 55.7%+13.6 pt | 38.9%−16.7 pt | 30.9%−8.1 pt | 28.1%−2.8 pt | 24.9%−3.2 pt | 24.7%−2.3 pt | · | · | · | |
| 36.4% | 26.9%−9.5 pt | 41.3%+14.4 pt | 50.2%+8.9 pt | 35.6%−14.6 pt | 30.1%−5.5 pt | 31.1%+0.9 pt | 31.4%+0.3 pt | 27.9%−3.5 pt | · | · | · | |
| 27.9% | 19.1%−8.8 pt | 31.9%+12.8 pt | 43.0%+11.2 pt | 19.1%−23.9 pt | 15.2%−3.9 pt | 15.0%−0.2 pt | 14.4%−0.6 pt | — | · | · | · | |
| Cash | ||||||||||||
| 1.8B | 2.0B+10.4% | 2.0B+0.2% | 6.5B+225.9% | 4.4B−32.2% | 3.9B−12.4% | 3.7B−5.4% | 4.1B+11.3% | 3.8B−2.4% | · | · | · | |
| 27.0% | 25.4%−1.6 pt | 23.6%−1.9 pt | 40.6%+17.0 pt | 36.3%−4.3 pt | 29.5%−6.8 pt | 25.8%−3.7 pt | 28.4%+2.6 pt | 24.2%−2.9 pt | · | · | · | |
| — | — | — | — | — | 0 | 0 | 370.3M | — | · | · | · | |
| Balance sheet | ||||||||||||
| — | — | 0.18x | 0.11x−0.07x | 0.09x−0.02x | 0.08x−0.01x | 0.07x−0.01x | 0.06x−0.00x | 0.06x−0.00x | · | · | · | |
| 114.80M | 114.60M−0.2% | 115.10M+0.4% | 112.20M−2.5% | 113.50M+1.2% | 113.70M+0.2% | 115.10M+1.2% | 108.60M−5.6% | 106.00M−2.4% | · | · | · | |
E = analyst consensus (revenue and EPS only). TTM = the twelve months to Jun 30, 2026: the last fiscal year, plus the quarters since, less the same quarters a year earlier. From the 10-K and the 10-Qs since, as accepted by the SEC; the shaded column is the latest period.